Total income grew by 23.13% year on year (YoY) to Rs 2,401 crore in the quarter ended 31 December 2024.

Profit before tax for the quarter was at Rs 726 crore, up 48.47% from Rs 489 crore reported in the same period a year ago.

Total expenses stood at Rs 1,675 crore in the third quarter of FY25, up 14.65% on YoY basis. Cost of material consumed was at Rs 1,021 crore (up 28.59% YoY) and employee benefit expenses stood at Rs 297 crore (up 10.82% YoY) during the period under review.

Forex gain for the current quarter amounted to Rs 10 crore as against a gain of Rs 18 crore posted in Q3 FY24.

On nine-month basis, the company’s net profit climbed 43.97% to Rs 1,529 crore on 22.25% rise in revenue from operations to Rs 6,775 crore in 9M FY25 over 9M FY24.

Forex gain for the nine-month period amounted to Rs 38 crore as against a gain of Rs 32 crore posted in same period a year ago.

Divi’s Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.